WO1988007869A2 | 1988-10-20 |
EP0304291A1 | 1989-02-22 | |||
US4599306A | 1986-07-08 | |||
EP0168745A2 | 1986-01-22 | |||
US4473555A | 1984-09-25 | |||
EP0103898A1 | 1984-03-28 |
DIALOG INFORMATION SERVICES, File 351, WORLD PATENT INDEX 81-90, Dialog Accession No. 3564867, OTSUKA PHARM K.K., "Peptide With Partial Amino Acid Sequence of Gamma-interferon Used to Prepare Specific Antibody for Gamma-interferon"; & JP,A,59 122 446, (14-07-84), 8434 (BASIC).
DIALOG INFORMATION SERVICES, File 154, Medline 83-90, Dialog Accession No. 07082681, LORD S.C. et al., "Functional Domains of Human Interferon Gamma Probed With Antipeptid Antibodies"; & MOL. IMMUNOL., July 1989, 26(7), p. 637-40.
DIALOG INFORMATION SERVICES, File 154, Medline 83-90, Dialog Accession No. 05868687, RUSSELL J.K. et al., "Epitope and Functional Specificity of Monoclonal Antibodies to Mous Interferon-gamma: the Synthetic Peptide Approach"; & J. IMMUNOL., 1 May 1986, 136(9), p. 3324-8.
DIALOG INFORMATION SERVICES, File 154, Medline 83-90, Dialog Accession No. 05713022, LEIST T. et al., "Antibodies to Synthetic Polypeptides Corresponding to Hydrophili Regions of Human Interferon Gamma"; & MOL. IMMUNOL., Aug. 1985, 22(8), p. 929-36.
1. | Peptides having 520 aminoacids corresponding to sequences of gamma interferon (IFN ) . |
2. | peptides according to claim 1 , selected in the group of 1 CysTyrCysGInAspProTyrValLysGluAlaGluΛsnLeu. (aa.114). |
3. | 2TyrValLysGluAlaGlu snLeuLysLysTyrPheAsnAla. (aa.720). |
4. | AsnLeuLysLysTyrPheAsnAlaGlyHisSerAspValAla. (aa.1328). |
5. | AsnAlaGlyHisSerAspValAlaAspAsnGlyThrLeuPhe. (aa.1932). |
6. | ValAlaAspAsnGlyThrLeuPheLeuGlyI!eLeuLysAsn. (aa.2538). |
7. | LeuPheLeuGlyIleLeuLysAsnT LysGluGluSerAsp. (aa.3144). |
8. | LysAsnTrpLysGluGluSerAspArgLysIleMetGlnSer. (aa.3750). |
9. | ScrAspArgLysIleMetGlnSerGlnIleValSerPheTyr. (aa.4356). |
10. | GlnSerGlnIleValSerPheTyrPheLysLeuPheLysAsn. (aa.4962). |
11. | PiieTyrPheLysLeuPheLysAsnPheLysAspAspGlnSer. (aa.5568). |
12. | LysAsnPheLysAspAspGlnSerIleGlnLysSerValGlu. (aa.6174). |
13. | GlnSerIleGlnLysSerValGIuThrIleLysGluAspMet. (aa.6780). |
14. | ValGluThrIIeLysGluAspMetAsnValLysPhePheAsn. (aa.7386). |
15. | AspMetAsnValLysPhePheAsnSerAsnLysLysLysArg. (aa.7992). |
16. | PheAsnSerAsnLysLysLysArgAspAspPheGIuLysLeu. (aa.8598). |
17. | LysArgAspAspPheGluLysLeuThrAsnTyrSerValThr. (aa.91104). |
18. | LysLeuThrAsnTyrSerValThrAspLeuAsnValGlnArg. (aa.97110). 18 ValThrAspLeuAsnValGlnArgLysAlaIIeHisGIuLeu. (aa.103116). 19 GlnArgLysAlaIleHisGluLeuIleGInValMetAlaGlu. (aa.109122). 20 GluLeuIIeGlnValMetAlaGluLeuSerProAlaAlaLys. (aa.115128). |
19. | 21 AlaGluLeuSerProAlaAlaLysThrGlyLysArgLysArg. (aa.121134). 2 AlaLysThrGlyLysArgLysArgSerGlnMetLeuPheGin. (aa.127140). |
20. | 23 LysArgSerGlnMetLeuPheGlnGlyArgArgAlaSerGln. (aa.133146). Use of the peptides of claims 1 , 2 for the determination of antiIFNy antibodies in the serum. Use of claim 3 wherein the determination is carried out by RIA, ELISA, fluoroimmunoassay methods. Use of the peptides of claims 1 2 for the affininitypurification of antiIFNy antibodies. Use of human antiIFNy antibodies for the preparation of a medicament for the treatment of conditions which may benefit of a selective immuno suppression of the pathological responses induced by IFNy . Use according to claim 1 wherein said conditions are type I Diabetes, Multiple sclerosis, Lupus erythematosus, Adjuvant arthritis, Schwartzamπn reaction, delayed hypersensitivity, ailotranspiant rejection. A pharmaceutical composition containing as active principle antiIFNy antibodies. Pharmaceutical composition according to claim 7 in unit dose form. Use of human antiIFNy antibodies for the purification of natural or recombinant IFNy . Use of human antiI FNy antibodies for the immunoanalysis of IFNy . |
NATURAL HUMAN ANTI-GAMMA INTERFERON ANTIBODIES
DETECTED AND PURIFIED BY SYNTHETIC PEPTIDES.
The invention relates to the use of human anti-gamma
interferon antibodies in human therapy and to the detection
and purification of said antibodies by means of • synthetic
peptides corresponding to regions of human gamma interferon.
Background Art
Interferons (IFNs) form an heterogeneous family of
proteins, defined according to their ability to prevent viral
replication. At present three major classes of human IFN have
been designed: human IFN-«( and IFN-β - which are 30% similar
at the primary amino acid sequence level - and IFN-y which is
similar to neither. IFN-y shares several characteristics and
activities with IFN-o( and IFN-β, but it also mediates various
immune functions. More recently, IFN-y has been established to
act as a potent immunomodulator (Table 1 ). Following
antigenic stimulation, T-cells and NK cells release IFN-y
which: influences the response of T-cells, B-ceils and
macrophages; enhances the proliferation of T-cells and the
functional maturation of cytotoxic T-cells; inhibits the
gereration of suppressor T-cells; enhances the immunoglobulin
secretion of B-cells when added late during an in vitro immune
response and switches on lgG2 a production. In addition to
these regulatory effects on the adaptative immune response,
IFN-y acts on the effector ceils of nonadaptive defence and
exerts proinfiammatory activity. Macrophages, primed with
IFN-y become able to kill bacteria, protozoa and tumor cells by
oxygen-dependent and-independent mechanisms. In • addition,
IFN-y induces endothelial cells and monocytes to release
chemiotactic factors, such as IL-1 and TNF and leads to
enhancement of synthesis and surface expression of class I and
class II antigens of the Major Histocompatibility Complex
(MHC), Fc receptor and leukocyte adhesion proteins (e.g.
integrins and integrin receptors). Induction of MHC antigens by
IFN-y may occur in several cell types that otherwise express
low or undetectable levels of these molecules. The
enhancement of MHC class II expression enables macrophages,
endothelial, epithelial and Langerhans ceils to present
antigens, but makes the same cells susceptible to the possible
cytotoxic effects of class II restricted T-lymphocytes. The
induction _of Fc receptors increases the capacity of
macrophages to phagocyte opsonized antigens. The
enhancement of the surface density of integrin receptors
promotes ' adhesion of monocytes to endothelial cells and to
immunological reactions.
While the general stimulatory activity of IFN- y in the
progression of immunologicai and inflammatory responses
indicates its potential therapeutical application as e.g.
immunomodulant, the agents that are able to neutralize its
activity may be beneficial when given to allotransplanted
patients and to patients affected by autoimmune disorders,
• chronic inflammation, septic shocks or diabetes (Table 2) and
any clinical state where an enhancement of IFN-y production is
considered to be detrimental.
Antibodies are the most inherently specific natural
immunosuppressive agents. Billiau (1988), Immunol. Today 9_,
37, reported that murine anti-IFN-y antibodies experimentally
inhibited the Shwartzman reaction. His experiments opened up
interesting clinical applications for the treatment of
Shwartzman-related or-like inflammatory reactions. Other
data reported by Jacob et al. (1987), J. Exp. Med. 1 66. 798,
showed that anti-IFN-y antibodies protect NZB mice against
spontaneous development of autoimmune disease. Their
experiments indicated that anti-IFN-y antibodies, policlonal or
preferably monoclonal, may be candidated for trials in
connective-tissue diseases, such as Systemic Lupus
Erythematosus (SLE) and Rheumatoid Arthritis, Multiple
Sclerosis, and possibly of all those diseases where activated
4 -
cell-mediated immunity needs to be depressed. Antibody
immunosuppressive therapy is used in certain instances in
humans, for preventing Rh-related Erythoblastosis Fetalis.
This treatment, however, is limited to diseases when the
causative antigen is known, and a specific human antiserum is
available.
As substances self-recognized by human immune system,
IFNs should not elicit antibodies in man except in conjunction
with autoimmune disorders or when their structure and
antigenicity are modified. Antibodies to IFN-y were reported by
Caruso et al. (1989) J. Biol. Reg. Homeost. Agents 2., 8, in
patients infected with Human Immunodeficiency virus (HIV).
More recently, Caruso et al. (1990) J. Immunol. 1 44. 685,
reported the presence of natural antibodies to IFN-y in healthy
individuals ranging from newborn babies to adults and, at
higher levels, in patients suffering from different viral
infections. Those antibodies specific to IFN-y were
affinity-purified from sera taken from healthy individuals, and
viral-infected patients or other different biological sources
(See,- "Modes for carrying out the invention"), by using a
recombinant IFN-y -coupled CNBr-activated Sepharose 4B
column. The antibodies were found to be mainly of the IgG
class, and jmantained their ability ot bind recombinant IFN-y.
The did not neu ralize antiviral activit of IFN- while bein
capable of suppressing the IFN-y induction of class II MHC
antigens and of Fc receptor sites for immunoglobulins. In
addition, the natural human anti-IFN-y antibodies were found
to interfere, in a mixed lymphocyte culture (MLC), with the
proliferation and cytotoxic generation of lymphocytes, by
inhibiting endogenously produced IFN-y. The availability of
affinity purified human anti-IFN- y antibodies, capable of
neutralizing the immunomodulatory activity of IFN-y , opens up
interesting clinical applications, possibly for all those
diseases where activated cell-mediated immunity needs to be
regulated.
The ready availability of neutralizing human anti-IFN-y
antibodies may solve many of the problems associated with
the administration of heterologous immunoglobulins, both
polyclonal and/or monoclonal antibodies, which can induce
anti-lg antibodies.
The main objective of the present invention is to provide
techniques to detect anti-IFN-y antibodies and affinity-purify
them, using synthetic peptides corresponding to regions of
human IFN-y.
Disclosure of the Invention
The invention is based upon the discovery that synthetic
peptides corresponding to regions of human IFN-y can
6 -
substitute the natural or recombinant IFN-y proteins in detecting and purifying natural human anti-IFN-y antibodies. Accordingly, the first aspect of the invention is the use of
synthetic peptides in different immunological methods to detect human antibodies to IFN-y. The above mentioned methods are based on the use of synthetic peptides capable to
specifically bind anti-IFN-y antibodies allowing their, direct or
indirect detection. The second aspect is a method to affinity-purify human anti-IFN-y antibodies using synthetic peptides. The method is based on the binding of synthetic peptides to a support, or to other molecular carriers or on trapping the peptides into nitrocellulose sheets.
The third aspect of the invention is an immunotherapeutic treatment to control a disease associated with an activated cell-mediated immunity. The treatment consists in the administration of human antibodies directed against IFN-y to the individual, sufficient to control the clinical aspects of the disease. The fourth aspect of the invention is a "unit dosage"
for treatment of the above-described patients. The unit dosage form consists of human antibodies against IFN-y combined with a pharmaceutically acceptable vehicle. The amount of human antibodies in the dosage form has to be sufficient to substantially lessen manifestation of the disease.
symptoms associated with the disease, and by the presence of
auto antibodies associated with the disease while they are
absent, or at lower titer, in healthy individuals.
The fifth aspect of the invention are immunological
methods to detect the IFN-y by the use of purified human
anti-IFN-y antibodies. The method comprises the use of human
anti-IFN-y antibodies to specifically bind and detect (in a
direct or indirect manner) the IFN-y molecule(s).
The last aspect of the invention is a method to
affinity-purify the IFN-y molecule(s) recognized by the human
anti-IFN-y antibodies. The method comprises binding of human
anti-IFN-y to a support, or to other molecular carriers or
trapping them into nitrocellulose sheets.
Brief description of the Drawing
Figure 1 represents a graph showing the inhibition of the
expression of Fc-receptor sites and HLA-DR antigens on U937
cells stimulated with recombinant IFN-y by human anti-IFN-y
antibodies.
Figure 2 presents a graph showing the effect of human
anti-IFN-y antibodies, added at different times, on MLC
proliferation.
Figure 3 presents a graph showing the effect of human
anti-IFN-y antibodies on the development of cytotoxicity in
MLC.
Figure 4 presents the chromatography of human anti-IFN-y
antibodies on a IFN-y -relating peptide-sulfolinked agarose
column.
Figure 5 presents a Western blot analysis of the anti-IFN-y
antibodies affinity purified by an IFN- -relating peptide based
column showing their specific reactivity with IFN-y.
Figure 6 presents a graph showing the effect of human
anti-IFN-y antibodies purified by a peptide-based affinity
column of MLC proliferation.
Figure 7 presents a graph showing the correlation obtained
by an IFN- -relating peptide based ELISA and a recombinant
IFN-y based RIA in detecting and quantify human anti-IFN-y
antibodies in human serum.
Modes for Carrying Out the Invention
The practice of the present invention will employ, unless
otherwise indicated, conventional techniques of molecular
Q _
biology, microbiology, recombinant DNA, chemistry,
biochemistry, biotechnology and immunology, which are within
the skill of the art. Such techniques are explained fully in the
literature (See Literature, Appendix 1).
According to the invention, it is very useful and of
relevance for scientists and clinicians, to detect and quantify
natural antibodies to IFN-y in specimens by any of the known
assays.
For example, assays to detect human anti-IFN-y antibodies
may be useful:
a) in clinic, for a rapid diagnosis of viral diseases, and to
distinguish between a viral and bacterial infection; to monitor
a viral infection and, eventually, a specific antiviral therapy;
to study anti-IFN-y antibodies in patients with cancer, viral
infections, and/or immunological disorders; to monitor organ
transplantation, for a rapid diagnosis of viral infections in
transplanted patients, in order to prevent an eventual
allotransplant rejection; to monitor antiviral as well as
immunomodulating therapies;
b) in industry, for the quality control of immunoglobulin
preparations obtained by chromatography or other preparative
methodologies;
c) in blood bank, to detect viral infections in apparently
healthy blood donors.
Immunoloofcal assays
Assays for detection of antibodies to IFN-y may be
developed -using natural and recombinant IFN-y , or IFN-y-
-relating peptides, of various lenghts, which are
representative of the different epitopes of the original
molecule. These assays may be based on any of the classical
RIA and ELISA techniques.
Microtiter plates, strips, wells or other solid phase
supports may be coated with the antigen with any suitable
technique known in the art, like overnight incubation at
various temperatures in appropriate buffers. The antigen used
for coating may be a single protein/peptide or a mixture of
different antigens depending upon the antibodies which have to
be detected. Antibodies may be detected in several specimens
like plasma, serum, cerebro spinal fluid, urine, saliva, tissue
culture fluids etc.
After incubation of the specimens with the antigen, the
bound antibody can be detected by addition of an enzyme
conjugated antiserum or monoclonal antibody. All the
traditional enzyme tracers can be employed in this assay
(horse radish peroxidase, alkaline phosphatase, etc.) and the
sensibility of the assay may be improved by use of any
biotiπ-avjdin or streptavidin system for detection of the
anafyte. The final detection can be achived by addition of a
substrate solution which is variable depending upon the
enzyme used.
Examples of idoneous substrate are o-phenylendiamine,
tetramethylbenzidine, paranitrophenylphosphate and others.
Results can be read by eye or by a spectrdphotometer and the
assay can be both qualitative or quantitative. Quantification
can be obtained by end point dilution, standard curve system or
by any other suitable quantification technique.
Any principle of assay can be used for the development of
an ELISA assay for detection of antibodies and particularly
they could be homogeneous assays or eterogeneous assays like
classical or modified competition assays, titration assays,
direct and indirect sandwich-assays, Ig capture assays and the
like.
The same principles used for detection of antibodies by
ELISA may be used by RIA or time resolved fluoroimmunoassay
or other assays based on the use of different tracers.
At the state of the art, antisera and monoclonal antibodies
obtained using natural and recombinant IFN-y can be used to
develop assays for detection of IFN-y in tissue culture fluids
and in biological specimens. Purified antibodies to IFN-y
obtained by affinity chromatography or other purification
procedures, may be used as well as antisera and monoclonal
antibodies and/or together with these reagents, for
U
development of antigen detection assays. All the conventional
thchniques may be applied to develop antigen detection assays
which may. be, for example, capture or competition
immunoassays (RIA, ELISA, TR-FIA etc.). To perform
competition immunoassays natural recombinant IFN-y, or IFN-y
-relating peptides can be used. They may be conjugated to
various tracer molecules. For example, they may be conjugated
to enzymes suitable for ELISA techniques, radioactive
materials for RIAs, fluorescent molecules for TRFIA and other
immunofljuorescent techniques, and others tracers. Detection
of antigen may also be obtained by immunofluorescence, flow
cytometry or other techniques known in the art.
Peptides
The general methodologies for obtaining peptides are well
known. Peptides of IFN-y may be obtained using different
methods:
a) Enzyme digestion and chemical cleavage of natural or
recombinant proteins. See, e.g., Arakawa et al. (1986), J. Biol.
Chem. 261. 8534; and Seeling et al. (1988), Biochem. Z∑, 1981.
b) Enzyme catalized synthesis in vitro. See, e.g., Mitin and
Zapevalova (1990), Int. J. Peptide Protein Res. &5_ 352.
c) Enzime modification of analogues.
d S nthesis b recombinant techni ues. See e. . Charbit
et al. (1987), J. Immunol. 139. 1658.
e) Site-specific and regionally directed mutagenesis of
protein-encoding sequences. See, e.g., Kunkel (1985), Proc.
Natl. Acad. Sci. U.S.A., fi£, 488.
f) Solution peptide synthesis. See, e.g., Bodansky (1984) in
Principles of Peptide synthesis, Springer-Verlag, Heidelberg;
Bodansky (1984), The practice of peptide synthesis,
Springer-Verlag, Heidelberg.
g) Solid-phase peptide synthesis. See, e.g., Sheppard
(1989), Solid Phase Peptide Synthesis, IRL Press, Oxford.
h) Segment condensation. See, e.g., Pettit (1976), in
Synthetic Peptides, Vol. 4, p22, Elsevier, Amsterdam.
i) And, in general, all the appropriate combinations of the
above mentioned methods.
The 146-amino acid sequence of mature human IFN-y,
deduced from the nucleotide sequence of a cloned cDNA is well
known. See, e.g., Gray et al. (1982) Nature, 295. 503, Grey and
Goeddel (1982), Nature 2 8, 859.
IFN-y -relating peptides of different lenghts may be
synthesized. For example, we have obtained IFN- -relating
peptides, spanning 14 residues which, at 7 amino acids
intervals, which cover all the native IFN-y primary sequence
from amino acid 1 (Cys) to amino acid 146 (Gin) (Table 3). This
list is not meant to be exhaustive, and shorter or longer
peptides within the sequence from peptide 1 to 23 (see table
3), may be obtained, combined, and used to detect or purify
natural human anti-IFN-y antibodies.
Provided that at least 5 aminoacids are present whereas
the upper limit is not critical but practical reasons limit the
maximum number of aminoacids to about 20. Particularly
preferred peptides are n° 1 , 2, 3, 9, 10, 11 ,13, 14, 15, 21, 22
in Table 3. IFN-y -relating peptides may have C-terminal
functions as free acid, alcohol, amide, ester, hydrazide, etc;
and N-terminat functisn modified. A number of techniques to
modify the N-terminal function are known in the art, the most
common are being acylation, aikylation, etc.
Some amino acid residues forming IFN-y-relating peptides
may be repeated, deleted or substituted in a conservative or
nonconservative manner. For example, amino acids from the
native structure of IFN-y may be substituted by other
uncorrelated amino acids that mimic the tertiary structure of
the epitope, forming a mimotope; amino acid residues may also
be replaced by pseudoisosteric aminoacids. Morover Methionine
can be replaced by N-Leucine or N-ethyl-Norleucine. Relevant
sequences may be also inserted into peptide skeleton to
increase its affinity to antibodies and its stability.
Peptides can also be conveniently giycosilated by
different su ars or modified su ar molecules. A number of
techniques for obtaining glycosilation of peptides are known in
the art. Peptides of IFN-y may be also modified in a way that
alter their backbone conformation. For example,
conformational constraints may be obtained inserting in the
peptide chain D-amino acids, alpha methyl amino acids, Proline
and other amino acids, even modified. See, e.g., Marshall and
Bassbard (1972), Circ. Res., Suppl., Suppl. II to 30, - 41 , 143;
Manavalan and Momany (1980), Biopolymers JJ 1943; Madison
and Kopple (1980), J. Am. Chem. Soc. 102. 4855.
Other possibilities of backbone modification may include
the C7 turn mimics of Huffman & Callahan, the β-turn mimics
of Freidingen, Kahn, Kemp and others. See, e.g., Huffman et al.
(1988). Peptides: Chemistry and Biology. Proc. 10th. American
Peptide Symp. (Marshall, G.R. ed.) pp 105-108, ESCOM, Leiden;
Freidingen, (1981) Peptides: Synthesis, Structure and Function,
Proc 774 American Peptide Symposium (Rich, D.H. & Gross, E.,
eds), pp. 673-783, Pierce Chemical Co., Rockford, IL; Kahn
(1988) Peptides, Chemistry and Biology, Proc. 10th American
Peptide Symp. (Marshall, G.R., ed.) pp. 109-111, ESCOM, Leiden;
Kemp & Sun (1982) Tetrahedron Lett. 22., 3759.
Peptide bonds may be modified so as to induce
conformational restriction or to increase stability to
enzymatic attack.
Peptide bonds modification can be either -C H< and
-CO-NH- without altering the N-C-C backbone atomic
sequence, for example C > - disubstituted peptides,
-β-dehydropeptides, thiated peptides, N-aikylated peptides,
N-hydroxylated peptides, nitrono peptides etc. Further
alterations may be obtained by N-C-C backbone modification
for example to form compounds containing d -hydroxy- or
it/ -amino acids; [yCH 2 0]; [y-CH (OH) CH 2 ]; [y-CH 2 -NH]; [ CH=CH].
These peptide surrogates or others can be used. See e.g.,
Spatola (1983) Chemistry and Biochemistry of Amino Acids
Peptides and proteins (Weinstein, B. ed.) Vol 7, pp 267-357,
Dekker, NY, McQuade et al (1990), Science, 247, 454, Miller et
al, (1989). For nomenclature see, e.g., IUPAC-1UB Commission
in Biochemical Nomenclature (1984) European J. Biochem., 138.
9. On the other hand IFN-y -relating peptides can be
conformationally restricted by either short-, medium- and
long-range cyclization to form homodetic cyclic peptides,
heterodetic cyclic peptides, bicyclic systems for instance
through N**-C [ , C *→C , C — C, N«C , C'^C 1 , N-N, or
spiro-system formation, or even by other techniques known in
the art. See, e.g., Toniolo, 1990, Int. J. Peptide Protein Res. 35.
287.
Nucleotides, nucieosides deossinucleotides oligo- and
polinucleotides, lipides, glycolipids, terpens and their analogs
Lipids, glycolipids, terpens, and appropriate derivates of
these compounds may be bound to the IFN-y-relating peptides.
INF-y -relating peptides may also be formed by various
combinations of modified or unmodified peptides, obtainable
by different techniques known in the art.
Carriers
Peptides may be linked, for different purposes (for
example, to facilitate their binding to a support), to a suitable
carrier to form a conjugate. Any carrier may be used, such as
the various serum albumins, tetanus toxoids, or keyhole limpet
hemocyanin (KLH) as in the state of the art.
Peptide-protein conjugates can be obtained basically
using simmetrical or asymmetrical bifunctional reagents. They
may be incorporated into the final conjugate or may activate
certain reactive sites on one molecule for the subsequent
linkage with the other one.
A number of techniques for obtaining such linkage are
known in the art, including glutaraldehyde, bis imido esters,
carbodiimides, imido esters, toluene diisocyanate,
p-nitrobenzoyl chloride, hystamine dihydrochloride, MBS
(Maleimidobenzoyl-N-hydroxysuccimimide) and many others.
Point of attachment of carrier molecules on a peptide can be
different, depending on the peptide structure and the steric
requirements. If the peptide lacks a sulphydryl, this can be
provided by addition of a cysteine residue. These reagents
create a disulfide linkage between themselves and peptide
cysteine residues on one side, and an amide linkage through the
£ -amino on a Lysin or other free amino group on the other. A
variety of such disulfide/amide-forming agents are known.
See, e.g., Immun. Rev. (1982) 62, 185. Other bifunctional
coupling agents form a thioether rather than a disulfide
linkage.
Binding of INF-y-relating peptides to the carrier molecule
may be achived by non covalent bonds. For example, a peptide
may be linked to a carrier protein through a hydrophobic
domain in a hydrophobic poket.
Purification
Human natural antibodies directed against IFN-y, can be
purified from different specimens, including plasma, serum,
urine, saliva, or already purified human immunogiobulin
preparations. Human immunoglobulins may include different
classes (IgM, IgG, IgA, IgD or IgE). They may be in the native
structure or denaturated under a variety of experimental
conditions knows in the art., or may include antigen binding
fragments (F(Ab') 2 , Fab, Fab 1 , FV) of immunoglobulins. The
antigen binding fragments of immunoglobulins may be obtained
chemically, enzymatically, or by recombinant DNA techniques,
e.g. miniantibodies.
Human natural antibodies to IFN-y can be purified by any of
the known affinity techniques, using IFN-y or IFN-y-relating
peptides as specific binding molecules linked to a support.
One of the many techniques known in the art. is the
affinity chromatography.
IFN-y-relating peptides may be linked to many of the
known matrices including Agarose, silica gel, polyacrylamide,
and the like.
Binding of peptides to the matrix may be achieved
cross-linking the functional groups on the matrix and on the
peptide by interposition of a spacer arm. Spacer arms most
often are linear aliphatic C6 - C8 chain with functional groups
able to form a bridge between matrix and peptide. Both
hydrophilic compounds (i.e., alcohols) and hydrophobic
compounds (i.e. spacer arms including a benzene ring or others
groups) can be used. Carrier molecules can be used instead of
spacer arms.
In order to avoid denaturation of the peptides following
their attachement to a matrix and to facilitate this process, it
may be useful to preactivate the matrix so that subsequent
binding of the iigand may be achieved under mild conditions.
Activation is a chemical reaction between the matrix and the
2 «• ϋ -
activating compound, thus resulting in the formation, at the
surface of the matrix itself, of reactive groups (usually
electrophiltc) which readily combine with groups of the Iigand
(usually nucleophiiic, e.g. amino groups). Reactive groups such
as imidocarbonate, oxirane (epoxy-activation) ,
trichlorotriazine, O-imidazolylcarbonyl, and many others are
known in the art. By reacting with an N-hydroxysuccinamide
ester of ' bromoacetic acid, a spacer arm with a terminal amino
group may be activated to give rice to a highly reactive
alkylating agent.
Ready to use matrices with activated spacer arms may be
used, such as, for example, SulphoLink coupling gel, in which
the active site is a iodoacetil group that readely react whith a
free sulphydryl group.
IFN-y-relating peptides may be also bound to a matrix by
non covalent bonds using, for example, a triazine dye resin.
Moreover, peptides of IFN-y may also be bound to a matrix by
reversible covalent bonds.
On the other hand, purified human antibodies to IFN-y may
also be linked to a support to affinity-purify the recognized
form(s) of IFN-y.
Affinity linkage between antibodies and IFN-y to the
affinity matrix can be broken either directly, by creating
conditions which are unfavourable for biospecific interactions
or by means of competitive affinity elution.
Therapy
Murine anti-IFN-y antibodies were shown to prevent the
rejection of allogeneic tumor cells, to inhibit the
Shwartzman-related or-like reaction, and to protect NZB mice
against spontaneous development of autoimmune diseases. See,
e.g., Landolfo et al. (1985), Science 229. 176, Billiau (1988),
Immunol. Today 9_. 37, Jacob et al. (1987), J. Exp. Med. 166. 798.
Purified human antibodies to IFN-y may be used in clinic as
specific antagonists of IFN-y to selective immunosuppress the
physiological response(s) induced by IFN-y , and more
specifically, those responses which are involved in the
up-regulation of the immune or autoimmune process. Being
proteins, the antibodies will be administered parentally,
preferably . intravenously. Since they may react with white
blood cells, they will preferably be administered slowly,
either from a conventional IV administration set or from a
subcutaneous depot. The dose for individuals, and for different
diseases, is determined by measuring the effect of the
anti-IFN-y antibody on the lessening of those parameters which
are indicative of the disease being treated. Based on the
experience of Jacob et al. (1988), J. Exp. Med. 166. 798, and
considering the natural clearance of antibodies, the dose of
human anti-IFN-y antibodies may have to be repeated
periodically depending upon the particular disease. When used
as prophylaxis, it may be possible to administer short courses
of human anti-IFN-y antibodies bimonthly, semiannually or
annually. In treating an existing disease it is expected a most
frequent antibody administration, also using infusion devices.
For autoimmune diseases that are known to be triggered or
aggravated by particular environmental factors which increase
the level of IFN-y, the dosage regimen will be scheduled
accordingly.
- When administered parentally, the human anti-IFN-
antibodies will be formulated in a unit dosage injectable form
(solution, suspension, emulsion) in association with a nontoxic
and nontherapeutic acceptable parental vehicle. Nonacqueous
vehicles may also be used. The vehicle may contain substances
that enhance isotonicity and chemical stability.- The antibody
is preferably formulated in purified form, substantially free of
aggregates and other proteins, at various concentrations
ranging approximately from 0.5 mg/ml to 20 mg/ml.
Examples
The ^following examples further illustrate the invention.
These examples are not intended to limit the scope of the
invention. In light of the present disclosure, numerous
embodiments within the scope of the claims will be apparent
to those of ordinary skill in the art.
I. Inhibition of natural and recombinant IFN-v-induced Fr.
receptor and HLA-DR antigens bv affinitv-purified human
anti-IFN-y antibodies.
U937 cells, when incubated in a medium containing
natural or recombinant IFN-y, increase both Fc receptor
and HLA-DR antigens on their surface. The maximal
effect is usually reached at 24h, using IFN-y at a
concentration of 200 U/ml.
As shown in figure 1 , when affinity-purified human
anti-IFN-y antibodies were present in U937 cell cultures
stimulated with IFN-y , they dramatically inhibited the
expected increase in Fc receptor and HLA-DR antigens.
The inhibition was .found to be dose-dependent (Table 4)
maximally effective with human anti-IFN-y antibodies at
a concentration of 4.8 At the same time no
inhibitory effect was observed when unrelated purified
human immunoglobulins were added, as a control, to IFN-y
treated U937 cell cultures.
Expression of Fc receptor sites (A, B, C), and HLA-DR
antigens (A 1 , B 1 , C 1 ) on U937 was evaluated by flow
cytometric analysis.
Continuous line: cultures set up in the absence of IFN-y.
Dotted line: cultures set up in the presence of IFN-y (A,
A 1 ), in the presence of IFN-y and human anti-IFN-y
antibodies (B, B 1 ), and in the presence of IFN-y and human
unrelated immunoglobulins (C, C).
I.A.1. Effect of human anti-IFN-y antibodies on the Ivmphocvte
proliferation induced bv irradiated allooeneic peripheral
blood leukocy es (PBL).
On day 7, mixed lymphocyte cultures result in marked
lymphocyte proliferation. The addition of human
anti-IFN-y antibodies at the beginning of the culture
resulted in a markedly reduced uptake of [ 3 H]thymidine.
Tfte inhibiting ability of human anti-IFN-y antibodies
was gradually lost with decreasing concentrations of
antibodies (Table 5). Figure 2 shows that lymphocyte
proliferation was inhibited when human antibodies
specific to IFN-y were added on days 0 and 1. When the
same antibodies were added later (days 2, 3, and 4), no
inhibition in proiiferative response was observed.
Purified human anti-IFN-y antibodies were added at the
concentration of 4.8 μg/well at the initiation of mixed
lymphocyte culture or on day 1 , 2, 3, 4. [ 3 H]thymidine
pulse for 18h on day 6.
I.A.2. Effect of human anti-IFN-y antibodies on allooeneic
induced Ivmphocvte cvtotoxicitv.
Figure 3 shows a representative experiment on the
cytotoxic response of mixed lymphocyte cultures,
evaluated on PHA-stimulated PBL or on K562 cells. The
cytotoxicity of effector cells, recovered from cultures
set up in the presence of human anti-IFN-y antibodies,
was strongly reduced against PHA-stimulated PBL. On
the other hand, the human anti-IFN-y antibodies had only
a moderate influence on the development of cytotoxic
lymphocytes to K562 cells. In other experiments, the
cytotoxic activity to K562 cells was reduced to only
10-20% as compared to control cultures. PBL were activated in vitro with irradiated allogeneic
PBL. Purified human antibodies to IFN-y (•) or unrelated
purified human immunoglobulins (o) were added, at the
concentration of 4.8 /jg/well, at the initiation of mixed
lymphocyte culture. (■ ) PBL kept with medium only.
Target cells were PHA stimulated lymphocytes (A) and
K562 (B).
I I. Chromatography of human anti-IFN-y on an agarose
matrix cross-linked through a spacer arm to peptide n°
22 (See Table 3_.
Two mg of peptide n° 22, provided with an additional
L-cysteine at its N terminal, was linked to 2 mi of
Sulfolink coupling gel (PIERCE) following a standard
protocol • recommended by PIERCE. The affinity column
was connected to an FPLC apparatus (PHARMACIA) and
equilibrated with phosphate buffered saline (PBS).
Purified human antibodies (50 mg) were applied to the
column at a flow rate of 0.1 ml/min., and the bound
antibodies were eluted at the same flow rate with 0.1 M
glycine, pH 3.0.
Figure 4 shows a typical pattern of elution of antibodies
bound to the affinity matrix (See, peak 2).
I II. Western blot analysis of the affinity-purified human
anti-IFN-y antibodies.
Antibodies specifically reacting to IFN-y, and purified on
a IFN-y -relating peptide based affinity column, were
, confirmed to be immunoglobulins and to react to
recgmbinant IFN-y by Western blot analysis. Figure 5
shows that by using 125 I-conjugated goat anti-human Ig
as a tracer, the anti-IFN-y antibodies, in a denaturated
form, were recognized as two reactive bands of 25,000
jand -50,000 molecular weight, being the light and heavy
chain of immunoglobulins respectively (a). At the same
time, these antibodies were capable of reacting with
- recombinant IFN-y proteins of 16,000 and 32,000
molecular - weight (Hoffmann-La Roche) (b). The
specificity % of the recombinant IFN-y reactivity of
purified human antibodies was confirmed by comparing
it with the reactivity of a commercially available
anti-IFN-y monoclonal antibody (Boehringer) (g).
Human anti-IFN-y antibodies did not react with natural
IFN- (gift of Dr. Kari Kantell) (b), natural IFN-β (Serono)
(c), recombinant IFN-c( (Hoffmann-La Roche) (e), and
recombinant interleukin-2 (Boehringer) (f).
IV. ELISA for detection of anti-IFN-y antibodies in human
serum.
Wells of polystyrene microtitration plates were coated
with IFN-y-relating peptides or recombinant IFN-y . In
order to quantify the amount of specific anti-IFN-y
antibodies in the specimens, a negative control and a
series of positive controls were included in each assay.
The positive controls were given a value of 1 , 25, 30,
50, 60 and 100 arbitrary antibody units (AU). A standard
curve was plotted for each test run referring to the
adsorbance of these controls and each test specimen
was given a value in AU based on such standard curve.
A panel of 88 serum specimens was used to study the
correlation of the results obtained from an ELISA based
on an IFN- -relating peptide (peptide n° 21 in this
example; See, Table 3) and a RIA based on recombinant
IFN- as antigen on the solid phase. As shown in figure 6,
the correlation between ELISA and RIA was very high,
with a correlation coefficient of 0,94, and 80,5% of the
results foiling within ± 1 SD from the theoretical values
indicated by the linear regression line.
Ut i l ity
The various embodiments of the invention are useful for
the detection, quantitation, purification of human anti-IFN-y
antibodies, and for treatment of individuals susceptible to
autoimmune diseases or, more in general, of individuals
suffering from all those diseases where activated
cell-mediated immunity needs to be depressed.
APPENDIX 1
Literature
Maπiatis, Fritsch and Sambrook, MOLECULAR CLONING: A
LABORATORY MANUAL (1982); DNA CLONING, Volumes I e II (D.N.
Glover ed. 1985); OLIGONUCLEOTIDE SYNTHESIS (M.J. Gait ed.
1984); NUCLEIC ACID HYBRIDIZATION (B.D. Hames and S.J.
Higgins; eds. 1984); ANIMAL CELL CULTURE (R.K. Freshney, ed.
1986); IMMOBILIZED CELLS AND ENZYMES (IRL Press, 1986); B.
Perbal, A P ACTICAL GUIDE TO MOLECULAR CLONING (1984);
- The series, METHODS IN ENZYMOLOGY (S. Clowick and N. Kaplan,
eds., Academic Press, Inc.), and HANDBOOK OF EXPERIMENTAL
IMMUNOLOGY, Volumes l-IV (D.M. Weir and C.C. Blackwell, eds.,
1986, Blackwell Scientific Publications); M. Bodanszky,
PRINCIPLES OF PEPTIDE SYNTHESIS (1984); K. March, ADVANCED
ORGANIC CHEMISTRY (1988); THE PEPTIDES, ANALYSIS,
SYNTHESIS, BIOLOGY (E. Gross and J. Meienhofer, eds., 1980,
Acxademic Press, Inc.); P. Tijssen, PRACTICE AND THERAPY OF
ENZYME IMMUNOASSAYS (R.H. Burdon and P.H. Van Knippenberg,
eds., 1988, Elsevier); LA. Osterman, METHODS OF PROTEIN AND
NUCLEIC ACID RESEARCH, Volumes 1-3 (Springer-Verlag);
PROTEIN ENGINEERING (D.L. Oxender and C.F. Fox, eds., 1988,
Alan R. Liss, Inc.).
Table 1. The IFN-γ multiple activities.
T-lymphocytes Promotes T lymphocytes proliferation. Induces maturation of cytotoxic T lymphocytes. Inhibits maturation of suppressor T lymphocytes
B-lymphocytes Promotes Ig synthesis and switch to IgG2a Inhibits IgE synthesis
Macrophages Induces or increases the expression of MHC class II, Fc receptor, Integrin receptors Mac-1, LFA-1, CR3; induces synthesis of IL-1, TNF, chemotactic factor. Increases release of proteolytic enzymes. Activates the oxidative burst and killing of microorganisms and tumor cells.
Endothelial cells Induces the expression of MHC class II and ICAM-1 and release of chemotactic factors.
Epithelial cells Induces the expression of MHC class II and ICAM-1.
PMN Enhances the release of proteolytic enzymes and oxidative radicals.
3 1
Table 2. Disease known to benefit of a therapy with IFN-γ antagonists.
Type I Diabetes Delayed by immunosuppressive agents. Exacerbated by IFN-y.
Multiple Sclerosis Exacerbated by IFN-γ.
Lupus-Erythematosus Delayed by anti-IFN- 7 MAbs.
Development of nephritis exacerbated by IFN-γ.
Adjuvant Arthritis Exacerbated by IFN-γ (early phase of the disease) and delayed by anti-IFN-γ MAbs.
Shwartzman Reaction Lethal effects of endotoxin, thrombosis and hemorrhagia prevented by anti-IFN-γ MAbs.
Delayed hypersensitivity Local recruitment of T cell inhibited by anti-IFN-γ MAbs.
Allotransplant Rejection Rejection of tumor skin and heart allografts delayed o blocked by anti-IFN-γ MAbs.
Table 3. Sequences of peptides of the invention
1 - Cys-Tyr-Cys-Gln-Asp-Pro-Tyr-Val-Lys-Glu-Ala-Glu-Λsn-Leu. (aa. 1-14).
2 - Tyr-Val-Lys-Glu-Ala-Glu-Asn-Leu-Lys-Lys-Tyr-Phe-Asn-Ala. (aa.7-20).
3 - Asn-Leu-Lys-Lys-Tyr-Phe-Asn-Ala-Gly-His-Ser-Asp-Val-Ala. (aa. 13-28).
4 - Asn-Ala-Gly-His-Ser-Asp-Val-Ala-Asp- sn-Gly-Thr-Leu-Phe. (aa. 19-32).
5 - Val-Ala-Asp-Asn-Gly-Thr-Leu-Phe-Leu-Gly-Ile-Leu-Lys-Asn. (aa.25-38).
6 - Leu-Phe-Leu-Gly-Ile-Leu-Lys-Asn-Trp-Lys-Glu-Glu-Ser-Asp. (aa.31-44).
7 - Lys-Asn-Trp-Lys-GIu-Glu-Ser-Asp-Arg-Lys-Ile-Met-Glπ-Ser. ' (aa.37-50).
8 - Ser-Asp-Arg-Lys-Ile-Met-Gln-Ser-Gln-Ile-Val-Ser-Phe-Tyr. (aa.43-56).
9 - Gln-Ser-Gln-Ile-Val-Ser-Phe-Tyr-Phe-Lys-Leu-Phe-Lys-Asn. (aa.49-62). 0 - Phe-Tyr-Phe-Lys-Leu-Phe-Lys-Asn-Phe-Lys-Asp-Asp-GIπ-Ser. (aa.55-68) 1 - Lys-Asn-Phe-Lys-Asp-Asp-Gln-Ser-Ile-Gln-Lys-Ser-Val-Glu. (aa. 61-74). 2 - Glα-Ser-Ile-Gln-Lys-Ser-Val-Glu-Thr-Ile-Lys-Glu-Asp-Met. (aa. 67-80). 3 - Val-Glu-Thr-Ile-Lys-Glu-Asp-Met-Asn-Val-Lys-Phe-Phe-Asn. (aa.73-86). 4 - Asp-Met-Asn-Val-Lys-Phe-Phe-Asn-Ser-Asn-Lys-Lys-Lys-Arg. (aa.79-92). 5 - Phe-Asn-Ser-Asn-Lys-Lys-Lys-Arg-Asp-Asp-Phe-Glu-Lys-Leu. (aa. 85-98). 6 - Lys-Arg-Asp-Asp-Phe-Glu-Lys-Leu-Thr-Asn-Tyr-Ser-Val-Thr. (aa. 91-104). 7 - Lys-Leu-Thr-Asn-Tyr-Ser-Val-Thr-Asp-Leu-Asn-Val-Gln-Arg. (aa. 97-110). 8 - Val-Thr-Asp-Leu-Asn-Val-Gln-Arg-Lys-Ala-Ile-His-Glu-Leu. (aa. 103-116). 9 - Gln-Arg-Lys-Ala-Ile-His-Glu-Leu-Ile-Gln-Val-Met-Ala-Glu. (aa. 109-122). 0 - Glu-Leu-Ile-Gln-Val-Met-Ala-Glu-Leu-Ser-Pro-Ala-Ala-Lys. (aa. 115-128). 1 - Ala-Glu-Leu-Ser-Pro-Ala-Ala-Lys-Thr-Gly-Lys-Arg-Lys-Arg. (aa. 121-134). 2 - Ala-Lys-Thr-GIy-Lys-Arg-Lys-Arg-Ser-Gln-Met-Leu-Phe-Gln. (aa. 127-140). 3 - Lys-Arg-Ser-Gln-Met-Leu-Phe-GIn-GIy-Arg-Arg-Ala-Ser-Gln. (aa. 133-146).
Table 4. Effect of natural human antibodies to IFN-y, added at differe concentrations on the expression of Fc receptor and HLA-D antigens on U937 cells stimulated with rlFN-y (a).
4.80 83.6 73.5 0.7
a. U937 cell cultures were stimulated for 24 hr with 200 U of rlFN-y a at the same time, they were treated or not with differe concentrations of human anti-IFN-y antibodies, or with purified hum unrelated Ig.
Table 5. Effect of human anti-IFN-y antibodies added at different concentrations on allogeneic induced lymphocytic proliferation (a).
Addition to [ 3 H] thymidine Inh ibition culture incorporation (%) (cpm + SD)
Exp. n. 1
97 32.9
0
0
Exp. n. 2
94 16
0
3.2
a. Lymphocytes admixed with irradiated allogeneic PBL, at a responder: stimulator ratio of 1 :1 , were incubated with medium alone or with medium containing different ratios of human antibodies to IFN-y , or of unrelated human antibodies. Proliferative response was measured on day 7 after 18 hr pulse with [ 3 H] thymidine.
Next Patent: POLYSACCHARIDE DERIVATIVES AND SEPARATING AGENT